menu search

ELEV / Why Is Elevation Oncology (ELEV) Stock Down 26% Today?

Why Is Elevation Oncology (ELEV) Stock Down 26% Today?
Elevation Oncology (NASDAQ: ELEV ) stock is taking a beating on Friday after the healthcare company announced a public stock offering. That public offering of ELEV stock has the company selling 17,810,000 shares at a price of $2.25 each. Read More
Posted: Jun 9 2023, 08:48
Author Name: InvestorPlace
Views: 102118

ELEV News  

Why Is Elevation Oncology (ELEV) Stock Down 26% Today?

By InvestorPlace
June 9, 2023

Why Is Elevation Oncology (ELEV) Stock Down 26% Today?

Elevation Oncology (NASDAQ: ELEV ) stock is taking a beating on Friday after the healthcare company announced a public stock offering. That public of more_horizontal

Steve Cohen's Point72 Disclosed 8.7% Stake In Elevation Oncology

By MarketBeat
May 30, 2023

Steve Cohen's Point72 Disclosed 8.7% Stake In Elevation Oncology

Elevation Oncology NASDAQ: ELEV is a biotech company that focuses on discovering and developing cancer therapies. The company aims to treat patients w more_horizontal

Why Is Elevation Oncology (ELEV) Stock Up 57% Today?

By InvestorPlace
May 26, 2023

Why Is Elevation Oncology (ELEV) Stock Up 57% Today?

Elevation Oncology (NASDAQ: ELEV ) stock is on the rise Friday despite a lack of news from the pharmaceutical company. There's no news that explains w more_horizontal

Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?

By Zacks Investment Research
March 23, 2023

Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?

Here is how Elevation Oncology, Inc. (ELEV) and Senesco Technologies Inc. (ELOX) have performed compared to their sector so far this year. more_horizontal

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

By PRNewsWire
May 26, 2022

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

Positive initial data support the potential of seribantumab to induce deep and durable benefit for patients with tumors harboring NRG1 fusions Clinica more_horizontal


Search within

Pages Search Results: